Next 10 |
2024-05-02 12:20:24 ET Summary Harrow, Inc. shares have dropped 45% since spring 2023, but the launch of Iheezo and Vevye suggest a potential rebound. Iheezo, an ocular anesthetic, has a substantial market opportunity and is expected to drive significant revenue for Harrow. Ve...
2024-05-02 04:42:01 ET Summary Harrow's long-term bull thesis is stronger than ever, but there may be a credible short-term bear thesis. The short-term bear thesis is the result of the Change Healthcare cyberattack, which has crippled reimbursement and caused huge financial headac...
2024-05-01 22:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Company to Host Conference Call to Discuss Results at 8:00 a.m. ET on May 14, 2024 Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after ...
2024-04-12 17:05:37 ET Gainers: Applied Optoelectronics ( AAOI ) +5% . Eliem Therapeutics ( ELYM ) +4% . Infinera Corporation ( INFN ) +4% . Harrow ( HROW ) +4% . Health Catalyst ( HCAT ) +4% . Losers: Eagle Pharmaceutica...
MELT-300 Pivotal Phase 3 Program Topline Readout Expected in Q4 2024 Melt Pharmaceuticals, Inc. (“Melt”), a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, today announced the completion of its Series B Preferred Stock fina...
2024-03-20 10:14:11 ET Harrow, Inc. (HROW) Q4 2023 Earnings Conference Call March 20, 2024 08:00 A.M. ET Company Participants Jamie Webb - Director-Communications & IR Mark L. Baum - Chairman and CEO Andrew R. Boll - CFO Conference Call Participants ...
2024-03-20 08:11:18 ET More on pre-market losers & stocks. Prudential: Consider Both Upcoming Results And 2024 Risk Factors Euronav NV: Not Backing Down On The Decarbonization Agenda Euronav NV 2023 Q4 - Results - Earnings Call Presentation Solidion Techn...
2024-03-20 01:11:43 ET More on Harrow Health Harrow's Drug Iheezo Is Off To A Great Start Harrow: Hedge Downside Risk With The 11.5% Yielding Baby Bonds Harrow: Temporary Disruption In Stock Price Creates Excellent Opportunity Harrow says dry eye drug Vevye n...
Full-Year 2023 Highlights: Revenues of $130.2 million, an increase of 47% over 2022 revenues of $88.6 million. GAAP net loss of $(24.4 million) compared with $(14.1 million) for the prior-year period. Adjusted EBITDA of $28.1 million, an increase of 116% over 2022 Adjusted EBITDA of...
News, Short Squeeze, Breakout and More Instantly...
Harrow Health Inc. Company Name:
HROW Stock Symbol:
NASDAQ Market:
2024-05-01 22:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Company to Host Conference Call to Discuss Results at 8:00 a.m. ET on May 14, 2024 Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after ...
Although U.S. stocks closed mixed on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence ...